爱维治对放疗所致急性口腔黏膜炎的疗效观察

目的:探讨爱维治对放疗患者急性口腔黏膜炎的临床效果及对炎性因子水平的影响。方法:选取青海省第五人民医院肿瘤科2015年7月—2017年9月收治的113例鼻咽癌放疗所致急性口腔黏膜炎患者,采用随机数字表法分为实验组（57例）、对照组（56例）,实验组采用爱维治治疗。对照组采用康复新治疗,对比2组患者治疗前、后疼痛程度（VAS评分）,口腔黏膜炎分级,血清C反应蛋白（c-reactiveprotein,CRP）,白细胞介素6（interleukin-6,IL-6）,转化生长因子β1（transforming growth factor-β1,TGF-β1）和肿瘤坏死因子α（tumor necrosis factor α,TNF-α）的变化。采用SPSS 16.0软件包对数据进行统计学分析。结果:治疗前,2组患者的VAS评分差异无统计学意义（P>0.05）;治疗后1周、2周,2组患者的VAS评分较治疗前均显著降低（P<0.05）,实验组患者的VAS评分显著低于对照组（P<0.05）;治疗后2周,实验组患者的口腔黏膜炎分级显著低于对照组（P<0.05）;治疗前,2组患者血清CRP、IL-6、TGF-β1、TNF-α水平差异无统计学意义（P>0.05）;治疗后2周,2组患者血清CRP、IL-6、TGF-β1、TNF-α水平较治疗前均显著降低（P<0.05）,实验组患者血清CRP、IL-6、TGF-β1、TNF-α水平显著低于对照组（P<0.05）。结论:爱维治对放疗患者急性口腔黏膜炎临床效果确切,能显著缓解患者的疼痛感、降低血清炎性因子水平。

Therapeutic effect of Actovegin on acute oral mucositis caused by radiotherapy

PURPOSE: To explore the clinical effect of Actovegin in the treatment of acute oral mucositis in patients with radiotherapy. METHODS: One hundred and thirteen patients with acute oral mucositis caused by radiotherapy for nasopharyngeal carcinoma admitted to the Department of Oncology, the Fifth People's Hospital of Qinghai Province from July 2015 to September 2017 were randomly divided into the experimental group (57 cases) and control group (56 cases). Patients in the experimental group were treated with Aiweizhi, while patients in the control group were treated with new rehabilitation. The changes of VAS score, oral mucositis grade, serum CRP, IL-6, TGF-β1 and TNF-α were compared between the 2 groups. The data were analyzed with SPSS 16.0 software package. RESULTS: Before treatment, there was no significant difference in VAS score between the 2 groups (P>0.05). After 1 week and 2 weeks of treatment, the VAS scores of the two groups were significantly lower than those before treatment (P<0.05). The VAS score of the experimental group was significantly lower than that of the control group (P<0.05). After 2 weeks of treatment, oral mucositis grade of the experimental group was significantly lower than that of the control group (P<0.05). There was no significant difference in serum CRP, IL-6, TGF-β1, and TNF-α level between the 2 groups before treatment (P>0.05). After 2 weeks of treatment, the level of serum CRP, IL-6, TGF-β1, and TNF-α in both groups was significantly lower than that before treatment (P<0.05). The serum level of CRP, IL-6, TGF-β1 and TNF-α in the experimental group was significantly lower than that in the control group (P<0.05). CONCLUSIONS: Actovegin has a clear clinical effect on acute oral mucositis in patients with radiotherapy, which can significantly alleviate the pain of patients and reduce the level of serum inflammatory factors.